A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer

Medical Oncology

Volumn 32, Issue 1, 2015, Pages 1-5

  Cao, Ranhua ^a,b   Zhang, Shuai ^a   Ma, Dedong ^a   Hu, Likuan ^a  

^a SHANDONG UNIVERSITY   (China)

^b Affiliated Hospital of Inner Mongolia Medical University   (China)

Author keywords

Bevacizumab; Chinese metastatic colorectal cancer; FOLFIRI; Second line chemotherapy

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHINESE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERTENSION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; BEVACIZUMAB; CAMPTOTHECIN; CHINA; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84919917989     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0325-9     Document Type: Article

References (12)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.
2. Zheng ZX, Zheng RS, Zhang SW, Chen WQ. Colorectal cancer incidence and mortality in china, 2010. Asian Pac J Cancer Prev: APJCP. 2014;15(19):8455–60.
3. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannesen TB, Starkhammar H, Topham CA, Awad L, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352(9138):1413–8.
4. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229–37.
5. Roque IFM, Sola I, Martin-Richard M, Lopez JJ, Bonfill Cosp X. Second-line chemotherapy in advanced and metastatic CRC. Cochrane Database Syst Rev. 2009;15(2):CD006875. doi:10.1002/14651858.CD006875.pub2.
6. Sorbye H, Berglund A, Tveit KM, Ogreid D, Wanderas EH, Wentzel-Larsen T, Dahl O, Glimelius B. Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer. Acta Oncol. 2007;46(7):982–8.
7. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005;23(15):3502–8.
8. Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539–44.
9. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499–506.
10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
11. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–81.
12. Horita Y, Yamada Y, Kato K, Hirashima Y, Akiyoshi K, Nagashima K, Nakajima T, Hamaguchi T, Shimada Y. Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial. Int J Clin Oncol. 2012;17(6):604–9.